In January through September 2012, the company reported a net profit of RON32.5 million.
Zentiva, a unit of French drug maker Sanofi-Aventis, said total sales rose 19.6% to RON242.5 million in the first nine months of 2013, from RON202.7 million a year earlier.
Revenues were up 13.5% to RON244.8 million, while costs increased 14% to RON200 million.
Zentiva forecasts a 49% increase in its full-year net profit to RON47.9 million in 2013, while sales are expected to rise 15.1% to RON300.2 million.
The company has a share capital of RON41.6 million split into 416.9 million shares with a face value of RON0.1.
French group Sanofi-Aventis owns 81.6% in Zentiva Romania.
Thursday, Zentiva’s shares closed up 1.84% at RON0.9675 in Bucharest. (EUR1=RON4.4536)